218 related articles for article (PubMed ID: 20235886)
41. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis.
Kumasaka T; Seyama K; Mitani K; Souma S; Kashiwagi S; Hebisawa A; Sato T; Kubo H; Gomi K; Shibuya K; Fukuchi Y; Suda K
Am J Surg Pathol; 2005 Oct; 29(10):1356-66. PubMed ID: 16160479
[TBL] [Abstract][Full Text] [Related]
42. Role of the CXCR4/CXCL12 axis in lymphangioleiomyomatosis and angiomyolipoma.
Clements D; Markwick LJ; Puri N; Johnson SR
J Immunol; 2010 Aug; 185(3):1812-21. PubMed ID: 20585037
[TBL] [Abstract][Full Text] [Related]
43. Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.
Prizant H; Hammes SR
Endocrinology; 2016 Sep; 157(9):3374-83. PubMed ID: 27409646
[TBL] [Abstract][Full Text] [Related]
44. Involvement of lymphatics in lymphangioleiomyomatosis.
Glasgow CG; Taveira-DaSilva A; Pacheco-Rodriguez G; Steagall WK; Tsukada K; Cai X; El-Chemaly S; Moss J
Lymphat Res Biol; 2009 Dec; 7(4):221-8. PubMed ID: 20143921
[TBL] [Abstract][Full Text] [Related]
45. Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells.
Lu Y; Liu X; Zhang E; Kopras EJ; Smith EP; Astreinidis A; Li C; Leung YK; Ho SM; Yu JJ
PLoS One; 2020; 15(2):e0228894. PubMed ID: 32078667
[TBL] [Abstract][Full Text] [Related]
46. Novel developments in the study of estrogen in the pathogenesis and therapeutic intervention of lymphangioleiomyomatosis.
Tai J; Liu S; Yan X; Huang L; Pan Y; Huang H; Zhao Z; Xu B; Liu J
Orphanet J Rare Dis; 2024 Jun; 19(1):236. PubMed ID: 38877584
[TBL] [Abstract][Full Text] [Related]
47. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells.
Yu JJ; Robb VA; Morrison TA; Ariazi EA; Karbowniczek M; Astrinidis A; Wang C; Hernandez-Cuebas L; Seeholzer LF; Nicolas E; Hensley H; Jordan VC; Walker CL; Henske EP
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2635-40. PubMed ID: 19202070
[TBL] [Abstract][Full Text] [Related]
48. Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis.
Young LR; Franz DN; Nagarkatte P; Fletcher CDM; Wikenheiser-Brokamp KA; Galsky MD; Corbridge TC; Lam AP; Gelfand MJ; McCormack FX
Chest; 2009 Sep; 136(3):926-933. PubMed ID: 19349386
[TBL] [Abstract][Full Text] [Related]
49. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.
Alayev A; Salamon RS; Sun Y; Schwartz NS; Li C; Yu JJ; Holz MK
Am J Respir Cell Mol Biol; 2015 Nov; 53(5):637-46. PubMed ID: 25844891
[TBL] [Abstract][Full Text] [Related]
50. Surfactant dysfunction and lung inflammation in the female mouse model of lymphangioleiomyomatosis.
Atochina-Vasserman EN; Guo CJ; Abramova E; Golden TN; Sims M; James ML; Beers MF; Gow AJ; Krymskaya VP
Am J Respir Cell Mol Biol; 2015 Jul; 53(1):96-104. PubMed ID: 25474372
[TBL] [Abstract][Full Text] [Related]
51. [Lymphangioleiomyomatosis].
Wirtz H
Zentralbl Chir; 2013 Oct; 138 Suppl 1():S59-74; quiz 75-6. PubMed ID: 24277558
[TBL] [Abstract][Full Text] [Related]
52. [Pulmonary lymphangioleiomyomatosis: From pathogenesis to management].
Chebib N; Khouatra C; Lazor R; Archer F; Leroux C; Gamondes D; Thivolet-Bejui F; Cordier JF; Cottin V
Rev Mal Respir; 2016 Oct; 33(8):718-734. PubMed ID: 26604019
[TBL] [Abstract][Full Text] [Related]
53. The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis.
Strizheva GD; Carsillo T; Kruger WD; Sullivan EJ; Ryu JH; Henske EP
Am J Respir Crit Care Med; 2001 Jan; 163(1):253-8. PubMed ID: 11208653
[TBL] [Abstract][Full Text] [Related]
54. Incidental Pelvic and Para-aortic Lymph Node Lymphangioleiomyomatosis Detected During Surgical Staging of Pelvic Cancer in Women Without Symptomatic Pulmonary Lymphangioleiomyomatosis or Tuberous Sclerosis Complex.
Rabban JT; Firetag B; Sangoi AR; Post MD; Zaloudek CJ
Am J Surg Pathol; 2015 Aug; 39(8):1015-25. PubMed ID: 25786086
[TBL] [Abstract][Full Text] [Related]
55. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
Makovski V; Haklai R; Kloog Y
Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
[TBL] [Abstract][Full Text] [Related]
56. Lymphangioleiomyomatosis: a disease involving the lymphatic system.
Seyama K; Kumasaka T; Kurihara M; Mitani K; Sato T
Lymphat Res Biol; 2010 Mar; 8(1):21-31. PubMed ID: 20235884
[TBL] [Abstract][Full Text] [Related]
57. Cross talk between LAM cells and fibroblasts may influence alveolar epithelial cell behavior in lymphangioleiomyomatosis.
Clements D; Miller S; Babaei-Jadidi R; Adam M; Potter SS; Johnson SR
Am J Physiol Lung Cell Mol Physiol; 2022 Feb; 322(2):L283-L293. PubMed ID: 34936509
[TBL] [Abstract][Full Text] [Related]
58. [Lymphangioleiomyomatosis - new concepts on pathogenesis, diagnosis and treatment].
Sobiecka M
Wiad Lek; 2016; 69(2 Pt 1):123-9. PubMed ID: 27421126
[TBL] [Abstract][Full Text] [Related]
59. mTOR treatment in lymphangioleiomyomatosis: the role of everolimus.
Yates DH
Expert Rev Respir Med; 2016; 10(3):249-60. PubMed ID: 26847859
[TBL] [Abstract][Full Text] [Related]
60. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses.
Hayashi T; Kumasaka T; Mitani K; Okada Y; Kondo T; Date H; Chen F; Oto T; Miyoshi S; Shiraishi T; Iwasaki A; Hara K; Saito T; Ando K; Kobayashi E; Gunji-Niitsu Y; Kunogi M; Takahashi K; Yao T; Seyama K
Hum Pathol; 2016 Apr; 50():34-42. PubMed ID: 26997436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
